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Abstract
Carriers of large recurrent copy number variants (CNVs) have a higher risk of developing neurodevelopmental disorders.
The 16p11.2 distal CNV predisposes carriers to e.g., autism spectrum disorder and schizophrenia. We compared subcortical
brain volumes of 12 16p11.2 distal deletion and 12 duplication carriers to 6882 non-carriers from the large-scale brain
Magnetic Resonance Imaging collaboration, ENIGMA-CNV. After stringent CNV calling procedures, and standardized
FreeSurfer image analysis, we found negative dose-response associations with copy number on intracranial volume and on
regional caudate, pallidum and putamen volumes (β=−0.71 to −1.37; P < 0.0005). In an independent sample, consistent
results were obtained, with significant effects in the pallidum (β=−0.95, P= 0.0042). The two data sets combined showed
significant negative dose-response for the accumbens, caudate, pallidum, putamen and ICV (P= 0.0032, 8.9 × 10−6, 1.7 × 10−9,
3.5 × 10−12 and 1.0 × 10−4, respectively). Full scale IQ was lower in both deletion and duplication carriers compared to non-
carriers. This is the first brain MRI study of the impact of the 16p11.2 distal CNV, and we demonstrate a specific effect on
subcortical brain structures, suggesting a neuropathological pattern underlying the neurodevelopmental syndromes.
Introduction
Carriers of large recurrent copy number variants (CNVs) are
at increased risk for developing autism spectrum disorders
(ASD), schizophrenia or intellectual disability [1]. While
the same CNV may confer risk for each of these neurode-
velopmental disorders, carriers show remarkable phenotypic
variability [2–5]. Magnetic resonance imaging (MRI) can
help unravel possible underlying brain consequences asso-
ciated with carrying these CNVs and provide novel insight
into neuropathological mechanisms [2, 6–10].
The neural correlates of a recurrent CNV at the distal
16p11.2 locus have remained unexplored, despite being
potentially very informative. Low copy repeats at the 16p11.2
locus drive the formation of recurrent CNVs (Fig. 1) [5, 11–15]
whose carriers experience increased risk for various
neurodevelopmental disorders [3, 16–25] or somatic traits and
diseases [17, 26–30]. Within the 16p11.2 region, the segment
with breakpoints (BP) at 28.3 and 28.9Mb (hg18, BP1–BP3) is
referred to as the distal region. Within this region, there is a
minimal core segment from 28.7 to 28.9Mb (hg18, BP2–BP3)
(Fig. 1) that contains nine genes. The deletion is associated
with obesity [26, 27], intellectual disability [26] and schizo-
phrenia [20, 22] and the duplication has been associated with
lower body mass index (BMI) [17, 31]. Both 16p11.2 distal
CNVs are associated with autism spectrum disorder [17] and
have been found in individuals with epilepsy [23]. Several
studies have been published about the microstructural effect on
the brain [6, 8, 32] and cognition [30, 33, 34] of the 16p11.2
proximal CNV (29.5–30.1 MB) (Fig. 1). In contrast, the bio-
logical basis of the 16p11.2 distal phenotypes, including a
possible effect on brain structure and cognition remains
unknown.
Large effect-size CNVs conferring risk for neurodeve-
lopmental disorders including major psychiatric disorders
[35] are rare (<0.25% in frequency). Assembling suffi-
ciently powered MRI samples to detect effects of rare CNVs
on brain morphometry is challenging. For instance, in the
Icelandic population [2] and the UK Biobank [36], the
frequencies of the 16p11.2 distal deletion are 0.019% and
0.012%, respectively. Likewise, the reciprocal duplication
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is found at a frequency of 0.038% and 0.030%, respec-
tively. Hence, studying rare pathogenic CNVs like 16p11.2
distal calls for collaborative efforts. The ENIGMA-CNV
consortium has collected a sample that currently includes
16,046 subjects with CNV and brain MRI data.
In recent studies, ‘mirrored phenotypes’ were described
in 16p11.2 distal CNV allele carriers for both weight
[17, 31] and head circumference [17]. On average, deletion
carriers had increased BMI and head circumference,
whereas duplication carriers had lower weight and smaller
head circumference. Here we investigated gene dose
response effects (i.e., effects dependent on the number of
genomic copies at the 16p11.2 distal locus) on brain
structural measures, including subcortical brain volumes,
total surface area, mean cortical thickness and intracranial
volume (ICV) in n= 6906 participants from primarily non-
familial population samples, in addition to clinical cohorts,
to resolve CNV effects relative to a general population
average.
Material and methods
Discovery sample description
Supplementary Table 1 contains information on study
design, participants, genotyping array, PFB-file and
reference for previous description on individual inclusion
and exclusion parameters for all 34 world-wide data sets
in ENIGMA-CNV; altogether 16,046 individuals with
CNV and MRI imaging data from the ENIGMA con-
sortium. The 16p11.2 distal sample consisted of a subset
of these individuals with twelve deletion carriers, twelve
duplication carriers and 6882 non-carriers from eleven
different cohorts and 14 scanner sites collected up until
1 July 2017. More demographic details are supplied in
Supplementary Note 1 and Supplementary Table 2 (on
CNV carriers).
CNV calls and validation
See Supplementary note 2 for details on CNV calling and
quality control. In short, carriers in the 16p11.2 European
consortium cohort were identified based on report from the
cytogeneticist. All other cohorts had CNVs called in a
unified manner using PennCNV [37]. Appropriate popula-
tion frequency (PFB)-files (Human Genome Build NCBI36/
hg18) and GC (content)-model files for each data set were
selected from the PennCNV homepage (Supplementary
Table 1).
Samples were filtered based on standardized quality
control metrics and CNVs overlapping the region of interest
(16p11.2 distal BP2–BP3 and BP1–BP3) were identified
and visualized with the R package iPsychCNV. The mini-
mally affected 16p11.2 distal region was covered well by all
the arrays in the study (Supplementary Figure 1). No car-
riers carried other genomic imbalances (as defined by
Supplementary Table 3) except six 16p11.2 distal-proximal
CNV (BP1–BP5) carriers from the 16p11.2 European
consortium sample (Supplementary Table 2).
Image acquisition and processing
Supplementary Table 4 outlines-specific technical details
concerning scanners and acquisition parameters. The brain
measures examined were obtained from structural MRI data
Fig. 1 Recurrent CNVs in the 16p11.2 region. CNVs are indicated
with reddish lines. All coordinates (in MB) are from the human gen-
ome build hg18/NCBI 36. This study includes CNVs overlapping the
core 16p11.2 distal region (BP2–BP3) of 220 kb (blue box). These
CNVs include the 16p11.2 distal BP2–BP3 (~220 kb), the 16p11.2
distal BP1–BP3 (~550 kb), the 16p11.2 distal BP1–BP4 (~800 kb) and
the 16p11.2 distal-proximal BP1–BP5 (~1.7MB) CNVs
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collected at participating sites and processed locally fol-
lowing the ENIGMA protocol. The analysis was based on
standardized image analysis, FreeSurfer, quality assurance
and statistical methods as per the harmonized neuroimaging
protocols developed within ENIGMA2 [38] and ENIGMA3
(http://enigma.ini.usc.edu/protocols/imaging-protocols).
More details are supplied in Supplementary Note 3.
Statistical analysis
Imaging data processing and CNV calling were performed
locally whereupon downstream analysis was performed
centrally in a mega-analysis with de-identified data.
The primary analysis for this paper focused on the full set
of subjects including family members and data sets with
patients to maximize the power to detect effects. Only one
of a pair of duplicates was kept. Individuals with a mini-
mum overlap of 0.4 to regions (R package iPsychCNV)
with known pathogenic CNVs (Supplementary Table 3)
were excluded from the analysis regardless of copy number
status. Only scanner sites with individuals carrying a
16p11.2 distal deletion or duplication were included. See
Supplementary Note 4 for description of control analyses
excluding either (a) individuals with an established neuro-
developmental diagnosis, (b) children below age 18, (c) first
and second-degree relatives or (d) carriers of the 1.7 MB
16p11.2 distal-proximal (BP1–BP5) CNV or (e) matching
each carrier with four controls or (f) testing the effect of
ancestry.
Brain measures were normalized in R 3.2.3 by an inverse
normal transformation of the residual of a linear regression
on the phenotype correcting for covariates. The final
covariance-corrected values (covariates= age, age squared,
sex, scanner site and ICV) were used in downstream ana-
lysis and are reported for each measure. ICV was not
included as a covariate in the analysis of ICV. For analytic
purposes, total cortical surface area and total average
thickness were normalized in the same way as subcortical
volumes. We also performed analysis excluding ICV from
the covariates.
For the dose response analysis (i.e., the effect on brain
structure of 16p11.2 distal copy number variation), a linear
regression on the copy number state of the individuals
(deletion= 1, normal= 2, duplication= 3) was performed
using the following model: covariance-corrected brain
measure ~ copy number (deletion= 1, non-carrier= 2,
duplication= 3).
For comparison between groups, a two sample two-sided
t-test assuming equal variance in all carrier/non-carrier
groups was employed (R 3.3.2) where deletion or duplica-
tion carriers were compared either to each other or to non-
carriers. Results were considered statistically significant if
they exceeded a Bonferroni-corrected P-value (P= 0.05/10
regions= 0.005). We report the uncorrected p-values
throughout the manuscript.
Effect size is calculated as the absolute effect size (the
difference in mean between the two copy number groups in
the t-test—which, in this case, equals Cohen’s d as the
standard deviation of the normalized brain measures is one)
and the estimate of beta in the linear regression. Plots were
generated using R library ggplot2 v2.2.1 [39].
deCODE replication sample
An independent sample of three 16p11.2 distal deletion and,
six duplication carriers, as well as 832 non-carriers was
obtained from deCODE Genetics, Iceland. CNVs were
called with PennCNV as described previously and visually
inspected. All 16p11.2 distal carriers were of the minimal
16p11.2 distal (BP2–BP3) CNV type. The individuals were
scanned at one scanner site as previously described [7]. The
statistical analysis was performed as for the primary dis-
covery sample.
Meta-analysis
A fixed effects model was used to generate summary effect
size estimates using a restricted maximum likelihood esti-
mator in the R-package metafor-package [40] (version 1.9-
9) using the effect size and calculated SD (for comparison
between groups) or standard error (for dose response) from
the discovery and replication sample as input. More details
can be found in Supplementary Note 5.
IQ, BMI and gene expression analysis
Individuals aged 18–65 years were recruited for cognitive
phenotyping based on a large genotyped sample from
deCODE. The Icelandic version of the Wechsler Abbre-
viated Scale of Intelligence (WASIIS) [41, 42] was admi-
nistered to 1693 non-carriers and all CNV carriers except
one deletion carrier. Another 455 controls and one deletion
carrier were tested with two subtests, Vocabulary and
Matrix Reasoning, from the Wechsler Adult Intelligence
Scale (WAIS-III) [43]. More details on tests are available in
Supplementary Note 6. Carriers of known pathogenic
CNVs (Supplementary Table 3) besides 16p11.2 distal as
well as individuals with neurodevelopmental or psychiatric
diagnoses were excluded from the analysis. IQ data were
not normally distributed and, consequently, the non-
parametric Kruskal–Wallis test (R, v3.2.3) was used to
test differences in IQ between carrier groups. To test pair-
wise differences (deletion carriers versus non-carrier-con-
trols, duplication carriers versus non-carrier-controls,
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deletion versus duplication carriers), we used Wilcoxon
rank test in R. We applied a significance threshold of 0.05,
without correction for multiple testing since this was sec-
ondary analyses. For description of BMI and gene expres-
sion analysis, see Supplementary Note 7.
Results
Study participants
In the ENIGMA-CNV discovery data set, we identified 12
16p11.2 distal deletion carriers and 12 duplication carriers
scanned at 14 MRI scanners, and 6882 non-carriers inves-
tigated at the same MRI scanners. Demographic data are
shown in Table 1. Most CNV carriers exhibited the minimal
16p11.2 distal CNV type (BP2–BP3) (Fig. 1), four CNVs
were of the extended type (BP1–BP3) and six CNVs
extended into the 16p11.2 proximal region (BP1–BP5)
(Supplementary Table 2, Supplementary Figure 1). None of
the participants carried additional known pathogenic CNVs
(Supplementary Table 3).
Of 24 CNV carriers, 10 had an established neurodeve-
lopmental diagnosis (Supplementary Table 2). The
remaining carriers either did not have one or were recruited
in studies from which diagnostic information was not
available (Supplementary Table 2, Table 1).
There was a significant age difference between the
groups (ANOVA, P= 0.003); the non-carriers were older
(mean age 43.5 years) in comparison to the deletion (27.8
years) and duplication carriers (31.2 years). In addition, an
established neurodevelopmental diagnosis was found in a
significantly smaller proportion of non-carriers (4.9%) in
comparison to deletion (58%) and duplication carriers
(25%) (Table 1).
Table 1 Demographic data, discovery and replication data
Discovery, ENIGMA-CNV Replication, deCODE
del con dup P del con dup P
Individuals 12 6882 12 3 832 6
Age (mean (sd)) 27.8 (20.4) 43.5 (20.0) 31.2 (19.6) 0.003 48.7 (14) 46.2 (12) 47.0 (15) NS
Sex= female (%) 6 (50%) 3724 (54%) 3 (25%) NS 2 (67%) 502 (60%) 1 (17%) NS
Established diagnosis, n (%) 7 (58%) 336 (4.9%) 3 (25%) <0.001 0 (0%) 158 (19%) 2 (33%) NS
Diagnosis type (%)a
ADHD 1 (8.3%)b 2 (<0.1%) 149 (18%) 2 (33%)
Autism 2 (17%) 1 (0.1%)
Bipolar 1 (8.3 %) 100 (1.5 %) 7 (0.8%)
Dysthymia 1 (8.3 %)c 1 (<0.1%)
Epilepsy 1 (8.3%) 101 (1.5%)
Enuresis 1 (8.3%)
Language disorder 1 (8.3%)c
MDD 13 (0.2%) 1 (8.3%)d
Schizophrenia 1 (8.3%) 119 (1.7%) 1 (0.1%)
Scanner sites 7 14 9 1 1 1
Types of arrayse 8 11 9 Various Various Various
Children, n (%) 5 (41.7%) 788 (11.5%) 5 (41.7%) <0.001 0 (0) 0 (0) 0 (0)
Close relative in data set, n (%) 5 (41.7%) 1994 (30.8%) 2 (16.7%) NS 3 (0%) 832 (0%) 6 (0%)
Age, sex, established diagnosis, diagnosis type, number of scanner sites, types of arrays, children (number of individuals below 18 years) and
individuals with close relatives (>3rd degree relatives) in the data set. P (p-value) is based on a χ2-test for categorical values and ANOVA for
continuous values (R-package, TableOne)
ADHD attention deficit disorder, MDD major depressive disorder, SCZ schizophrenia, del deletion carrier, con non-carriers, dup duplication
carrier, NS non-significant
aDiagnosis type specifies the total number within each carrier group with an established neurodevelopmental or psychiatric diagnosis
bIn addition to Specific Learning disorder
cIn addition to Moderate ID and Speech Sound disorder
dIn addition to Social Anxiety disorder
eThe arrays for ENIGMA-CNV are specified in Sup Table 1
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Brain imaging results in the discovery sample
After correction for age, age squared, sex and scanner site, we
found a significant negative correlation between the number
of 16p11.2 distal copies (deletion= 1, non-carrier= 2,
duplication= 3) and ICV (β=−0.71, P= 5.1 × 10−4)
(Table 2, Fig. 2a) after correction for multiple testing (sig-
nificance threshold P < 0.005= 0.05/10 brain structures ana-
lysed), showing smaller ICV in duplication carriers compared
to deletion carriers. The uncorrected ICV plotted against age
stratified by scanner site are shown in Fig. 2b.
We evaluated whether the 16p11.2 distal CNV affected
seven subcortical (accumbens, caudate, putamen, pallidum,
amygdala, hippocampus and thalamus) and two cortical
(total surface area and mean cortical thickness) phenotypes.
After adjusting subcortical and cortical volumes for age, age
squared, sex, scanner site and ICV, the volumes of caudate,
pallidum and putamen were negatively associated with
the number of 16p11.2 distal copies with significance
at the multiple testing threshold (β=−0.87, P= 2.0 × 10−5;
β=−1.06, P= 2.2 × 10−7 and β=−1.37, P= 1.8 × 10−11,
respectively) (Table 2, Fig. 2a). Plotting the unadjusted
volumes of caudate, pallidum and putamen against the age
of participants revealed a consistent pattern (deletion car-
riers with larger and duplication carriers with smaller sub-
cortical volumes in comparison to non-carriers) for all
scanner sites for putamen and pallidum volume and almost
at all sites for caudate (Supplementary Figure 3a-c). This
shows that our findings are robust and not dependent upon a
few scanner sites.
To assess non-specific associations, we re-analyzed
subcortical volumes without correcting for ICV. As
expected, the absolute effect sizes of copy number on
the volumes of caudate, pallidum and putamen increased
(β=−1.18, P= 6.8 × 10−9; β=−1.27, P= 4.7 × 10−10
and β=−1.57, P= 1.4 × 10−14, respectively) and the
association with the volumes of the rest of subcortical
structures, except amygdala and hippocampus, became
significant (Supplementary Table 5).
To test for the presence of nonlinear differences between
deletion and duplication carriers, and deletion or duplication
carriers and non-carriers, we conducted individual t-tests
between these groups. We confirmed a negative dose
response with increasing copy number for the volumes of
the caudate, pallidum, putamen and for ICV but no addi-
tional structures revealed significant associations at sig-
nificance threshold of <0.005 (Table 3, Supplementary
Table 6, Supplementary Figure 3a-c).
To confirm the validity of the results, we carefully
checked for the impact of removing subjects known to carry
a neurodevelopmental diagnosis, children below age 18,
first and second-degree relatives or CNV carriers whose
CNVs extended into the 16p11.2 proximal region (Sup-
plementary Tables 5 and 6). Likewise, we redid the analysis
matching each carrier with four non-carriers for sex, age,
diagnosis status (with/without neurodevelopmental diag-
nosis) and scanner site and finally in a separate analysis we
controlled for population stratification in cohorts with
available ancestry (Supplementary Table 7). None of these
analyses changed the main results.
Table 2 Dose response of 16p11.2 distal copy number on subcortical volumes
ENIGMA-CNV, discovery deCODE, replication Combined (discovery+ replication)
Brain measure β P β P Q p(Q) I2 β CI, β, lower CI, β, upper P
Accumbens −0.49 0.025 −0.65 0.05 0.163 0.69 0 −0.54 −0.9 −0.18 0.0032*
Amygdala −0.21 0.31 −0.13 0.7 0.043 0.84 0 −0.19 −0.52 0.15 0.27
Caudate −0.87 2.0E–05** −0.46 0.17 1.13 0.29 11.4 −0.76 −1.1 −0.42 8.9E–06**
Hippocampus −0.14 0.48 −0.03 0.94 0.0813 0.78 0 −0.11 −0.45 0.22 0.52
Pallidum −1.06 2.2E–07** −0.95 0.0042* 0.0813 0.78 0 −1.03 −1.37 −0.7 1.7E–09**
Putamen −1.37 1.8E–11** −0.7 0.034 3.01 0.083 66.8 −1.19 −1.53 −0.85 3.5E–12**
Thalamus −0.33 0.11 −0.37 0.27 0.0105 0.92 0 −0.34 −0.69 0.01 0.054
Surface Area −0.09 0.66 0.14 0.68 0.355 0.55 0 −0.03 −0.36 0.31 0.87
Thickness −0.29 0.16 −0.02 0.94 0.49 0.48 0 −0.22 −0.55 0.12 0.2
ICV −0.71 5.1E–04* −0.54 0.1 0.194 0.66 0 −0.66 −1 −0.33 1.0E–04**
The effect size (β of the linear regression) is presented. A linear regression based on the copy number state of the individuals (deletion= 1, non-
carrier= 2, duplication= 3) was performed on normalized brain measures correcting for age [2], age, sex and scannersite (and ICV) in the
ENIGMA-CNV (discovery) and deCODE (replication) cohorts. Results were considered statistically significant if they were below a Bonferroni-
corrected P-value of 0.005 (0.05/10 regions). A final effect size estimate of the combined sample was obtained using a fixed effects meta-analysis
framework
CI confidence interval, Q statistics for the test for heterogeneity, p(Q) p-value for the test for heterogeneity, I2 heterogeneity levels
*P < 0.005
**P < 0.0005
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Replication in an independent cohort
We performed replication of the subcortical findings in an
Icelandic MRI sample (deCODE) comprising 841 indivi-
duals (3 deletion and 6 duplication carriers, 832 non-car-
riers) (Table 1). The negative correlation between the
number of 16p11.2 distal copies and the volume of pallidum
was confirmed (β=−0.95, P= 0.0042) (Fig. 3, Table 2) at
a significance threshold of <0.005. For volumes of the
caudate, putamen and for ICV, effects were in the same
direction as in the discovery sample, albeit not significant
(β=−0.46, P= 0.17; β= -0.70, P= 0.034; β=−0.54,
P= 0.10, respectively) (Fig. 3, Table 2). Apart from cortical
surface area, we observed the same direction of effect in the
replication sample as in the discovery sample (Table 2,
Fig. 3). For nonlinear differences, all directions of effect
were the same for subcortical volumes in the discovery and
replication data sets (Table 3, Supplementary Figure 4a-c).
The combined analysis of the ENIGMA and the
deCODE samples is shown in Table 2 and Fig. 3. Volumes
of caudate, pallidum, putamen and ICV decreased with
increasing number of 16p11.2 distal copies (β=−0.76,
P= 8.9 × 10−6; β=−1,03, P= 1.7 × 10−9; β=−1.19,
P= 3.5 × 10−12; β=−0.66, P= 1.0 × 10−4, respectively).
In the combined analysis, the volume of the accumbens also
revealed a significant association with the 16p11.2 distal
copy number (β=−0.54, P= 0.0032) (Tables 2 and 3,
Fig. 3, Supplementary Figure 4a-c).
Fig. 2 Measures of caudate, pallidum, putamen and ICV show a dose
response to differences in copy number in the 16p11.2 distal region.
All analyses were corrected for age, age squared, sex, scanner site and
ICV (except for ICV). Deletion carriers (del) in red, non-carriers (con)
in grey and duplication carriers (dup) in blue, respectively. a Boxplots
of subcortical volumes, surface area and thickness and ICV. The
normalized brain values are presented. Boxplots represent the mean.
Significant differences after Bonferroni correction between groups are
noted as *P < 0.005, **P < 0.0005. Centre line represents median, box
limits are the upper and lower 25% quartiles, whiskers the 1.5 inter-
quartile range and the points are the outliers. b Bivariate plot of age
versus uncorrected ICV
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Intelligence quotient (IQ)
Full scale IQ data were available for four 16p11.2 distal
deletion and twelve duplication carriers and 2148 non-
carriers from the Icelandic sample. None of these indivi-
duals had an established neurodevelopmental diagnosis, or
other known pathogenic CNVs (as defined by Supplemen-
tary Table 3). Analysis showed a significant difference in IQ
between groups (P= 0.0042). Both deletion (median IQ=
68.5) and duplication carriers (median IQ= 93) presented a
significantly lower IQ (P= 0.011, P= 0.035) than non-
carriers (median IQ= 101.5) (Supplementary Table 9,
Supplementary Figure 5) at a significance threshold of
P < 0.05.
Body mass index (BMI)
BMI data for mega-analysis were available for six cohorts
from ENIGMA-CNV counting seven deletion and seven
duplication carriers in addition to 1880 individuals without
a 16p11.2 distal CNV (Supplementary Table 9). BMI z-
scores were different between the carrier groups
(Kruskal–Wallis, P= 0.009, Supplementary Figure 6,
Supplementary Table 10). Duplication carriers had
Table 3 T-test on subcortical volumes between different 16p11.2 distal copy number groups
ENIGMA-CNV, discovery deCODE, replication Combined, discovery+ replication
Brain measure Cohens D P Cohens D P n, CN1 n, CN2 Q p(Q) I2 Cohens D CI, lower CI, upper P
Deletion vs duplication
Accumbens −0.99 0.023 −1.86 0.044 13 17 0.99 0.32 0 −1.17 −1.87 −0.47 1.0E–03*
Amygdala −0.42 0.32 −0.27 0.73 15 18 0.031 0.86 0 −0.38 −1.09 0.32 0.28
Caudate −1.74 0.0013* −1.25 0.25 15 18 0.251 0.62 0 −1.63 −2.44 −0.82 8.0E–05**
Hippocampus −0.29 0.57 −0.16 0.79 15 18 0.034 0.85 0 −0.22 −0.91 0.47 0.53
Pallidum −2.11 1.8E–05** −2.19 0.0038* 15 18 0.0091 0.92 0 −2.13 −2.79 −1.47 3.2E–10**
Putamen −2.73 5.3E–06** −1.67 0.089 15 18 0.77 0.38 0 −2.58 −3.41 −1.74 1.4E–09**
Thalamus −0.66 0.18 −0.85 0.045 15 17 0.079 0.78 0 −0.76 −1.41 −0.1 0.024
Surface area −0.18 0.69 −0.04 0.96 15 18 0.012 0.91 0 −0.16 −0.98 0.66 0.7
Thickness −0.58 0.25 0.17 0.84 15 18 0.53 0.47 0 −0.41 −1.26 0.45 0.35
ICV −1.41 0.0084 −0.70 0.4 15 18 0.65 0.42 0 −1.19 −1.99 −0.4 0.0034*
Deletion vs non-carrier-controls
Accumbens −0.54 0.088 −1.78 0.0019* 13 2467 3.1 0.078 67.8 −0.73 −1.22 −0.23 0.0039*
Amygdala 0.08 0.79 −0.15 0.8 15 3578 0.11 0.74 0 0.04 −0.49 0.56 0.89
Caudate −0.63 0.027 −1.12 0.05 15 3574 0.46 0.5 0 −0.79 −1.45 −0.12 0.02
Hippocampus −0.26 0.37 −0.23 0.69 15 3578 0.0031 0.96 0 −0.24 −0.75 0.27 0.35
Pallidum −0.82 0.0043* −1.52 0.0081 15 3577 0.87 0.35 0 −0.95 −1.51 −0.38 1.0E–03*
Putamen −1.72 2.4E–09** −1.24 0.031 15 3584 0.18 0.67 0 −1.67 −2.35 −0.99 1.5E–06**
Thalamus −0.3 0.3 −0.59 0.3 15 3571 0.24 0.62 0 −0.42 −1 0.16 0.15
Surface area 0.24 0.4 −0.50 0.38 15 4312 0.41 0.52 0 0.14 −0.61 0.9 0.71
Thickness −0.28 0.32 0.43 0.45 15 4312 0.66 0.42 0 −0.13 −0.83 0.58 0.73
ICV −0.44 0.13 0.23 0.7 15 4314 0.97 0.33 0 −0.26 −0.85 0.32 0.38
Non-carrier-controls vs duplication
Accumbens −0.34 0.26 −0.08 0.84 4433 17 0.25 0.62 0 −0.27 −0.73 0.19 0.26
Amygdala −0.46 0.11 −0.13 0.76 4533 18 0.41 0.52 0 −0.36 −0.83 0.11 0.13
Caudate −1.04 3.0E−04** −0.12 0.77 4617 18 1.9 0.17 46.2 −0.92 −1.37 −0.47 6.1E−05**
Hippocampus 0.06 0.85 0.08 0.84 4557 18 0.0030 0.96 0 0.07 −0.35 0.49 0.75
Pallidum −1.1 0.00013** −0.66 0.1 4504 18 2.3 0.13 56.5 −0.86 −1.14 −0.58 1.9E−09**
Putamen −0.85 0.0031* −0.44 0.28 4454 18 0.99 0.32 0 −0.7 −1.09 −0.31 4.9E−04**
Thalamus −0.33 0.27 −0.25 0.54 4562 17 0.063 0.8 0 −0.27 −0.5 −0.03 0.025
Surface area −0.33 0.25 0.46 0.26 4575 18 3.0 0.086 66.1 −0.19 −0.53 0.16 0.28
Thickness −0.28 0.33 −0.24 0.55 4578 18 0.0054 0.94 0 −0.27 −0.75 0.21 0.28
ICV −0.88 0.0023* −0.93 0.022 4690 18 0.0068 0.93 0 −0.9 −1.45 −0.35 0.0014*
Deletions versus duplication carriers, deletion carriers versus non-carriers and non-carriers versus duplication carriers in ENIGMA (discovery),
deCODE (replication) and the combined sample. T-tests were performed on normalized values of brain measures correcting for age [2], age, sex
and scanner site (and ICV). Results were considered significant if they were below a Bonferroni-corrected P-value of 0.005 (0.05/10 regions). A
final Cohen’s d-effect size estimate of the combined sample was obtained using a fixed effects meta-analysis framework
CI confidence interval, Q statistics for the test for heterogeneity, p(Q) p-value for the test for heterogeneity, I2 heterogeneity levels
*P < 0.005
**P < 0.0005
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significantly lower BMI z-scores (median; SD=−0.65;
1.61) than the non-carriers (0.43; 1.19; P= 0.048). Also,
the duplication carriers tended to have lower BMI z-scores
than the deletions (−1.56; 1.1, P= 0.052; Supplementary
Figure 6, Supplementary Table 10) and deletion carriers
tended to have higher BMI z-scores than non-carriers (P=
0.18) (Supplementary Table 10). For detailed information
on individual carriers, see Supplementary Table 2.
Discussion
This is the first study to determine the brain structure
underpinnings of the 16p11.2 distal recurrent CNVs. We
found a common denominator for 16p11.2 distal carriers
across different clinical phenotypes in a dose response
effect of copy number on the volumes of basal ganglia
(caudate, putamen and pallidum) (Table 2, Figs. 2 and 3).
The observed associations were independent of the presence
of neurodevelopmental diagnosis and the ancestry of par-
ticipants (Supplementary Tables 5 and 7). These effects
were consistent in the independent replication sample
(Fig. 3, Tables 2 and 3). Together with the result of lower
IQ in carriers, these findings provide new insight into
genetic mechanisms of brain structures and pathobiological
processes involved in neurodevelopmental disorders.
There are nine genes in the core 16p11.2 distal
(BP2–BP3) region. We tested the expression level of these
Fig. 3 Forest plots on the dose response of copy number on subcortical
volumes, surface area, thickness and ICV. The effect size (β of the
linear regression) at each site for each measure is shown by the
position on the x-axis. Standard error is shown by the horizontal line.
A summary polygon shows the results when fitting a random-effects
model to the two groups: ENIGMA-CNV discovery and deCODE
replication samples. del, con and dup denote the number of individuals
in each analysis. *P < 0.005, **P < 0.0005. Effect size and confidence
intervals are to the right
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in blood in available transcript data from two of our deletion
carriers (BP1–BP3) and compared with 234 non-carriers
(Supplementary Figure 7, Supplementary Table 11). Several
transcripts of the nine genes were relatively decreased in
blood. Due to the low numbers, only trends can be sug-
gested from these data but we find the down-regulation of
LAT gene expression to ~65% in 16p11.2 distal carriers
(Supplementary Figure 7, Supplementary Table 11) parti-
cular interesting due to recent results in zebrafish: These
showed that of the nine genes in 16p11.2 distal, only over-
expression of LAT induced a decrease in cell proliferation in
the brain with a concomitant microcephaly phenotype [44].
In parallel, LAT knockout mice showed brain anatomy
changes [44]. According to the Allen Brain Atlas, LAT
shows the highest expression in cerebellum and structures
of the basal ganglia (data not shown). Thus, high expression
of LAT overlaps with the position of brain structural chan-
ges identified in the present study. This further implicates
LAT, an immune signaling adaptor, as a possible dosage-
dependent driver of the CNV-associated brain phenotypes
including the basal ganglia.
By comparing the effect of a range of CNVs on the brain,
it is possible to identify patterns of effects related to the
genes involved, and thus learn about biological mechan-
isms. All three CNVs previously shown to have an effect on
ICV, 16p11.2 proximal [6, 8], 22q11 [9] and Williams
Syndrome [45], have concomitantly identified an effect on
either cortical surface area and/or cortical thickness. We
observed no effect on cortical surface area or cortical
thickness in 16p11.2 distal carriers (Table 2, Figs. 2 and 3).
This does not rule out the presence of smaller effects on
individual cortical areas. However, it may suggest a dif-
ferent impact on brain development mechanisms between
these three CNVs [6, 8, 9, 45] and 16p11.2 distal.
CNVs in the two neighboring regions 16p11.2 distal and
16p11.2 proximal show overlapping phenotypes: they both
dispose to various neurodevelopmental diseases and both
show a positive dose response for head circumference and
weight [17]. In addition, we found negative dose response
effects for the 16p11.2 distal CNV on ICV, putamen and
caudate volumes with effect size estimates comparable to
those previously reported for the 16p11.2 proximal CNV
[8]. Recently, a lymphoblastoid cell line study of chromo-
somal interaction in the 16p11.2 region suggested that the
two adjacent 16p11.2 distal and 16p11.2 proximal regions
(Fig. 1) interact [17]. The identified brain commonalities
could further support a mechanism in which the similar
phenotypic patterns are caused by disruption of the
chromatin structure surrounding the entire 16p11.2 region
[17, 32].
In this study, the CNVs (3 deletions and 3 duplications)
of six carriers extend into the adjacent 16p11.2 proximal
region. Redoing the analysis with exclusively 16p11.2 distal
carriers did not result in a change in effect size (Supple-
mentary Tables 5 + 6), suggesting that 1.7 MB distal-
proximal (BP1–BP5) CNV carriers are not the main cause
of the signal. A previous analysis from Loviglio et al. [44]
suggests an additive effect of two 16p11.2 regions (distal+
proximal) on human head circumference and weight.
Together with our data, this indicates both separate and
overlapping effects for the two CNVs and underlines the
importance of studying specific CNVs independently
despite overlapping phenotypes.
Interestingly, deletions and duplications of both 16p11.2
proximal and distal CNVs are associated with ASD [17, 19].
However, only the proximal duplication and the distal
deletion are associated with schizophrenia [20, 22]. This
difference in phenotype association between these bordering
CNVs may indicate specific differences in the pathological
mechanisms of ASD and schizophrenia.
We observed a decrease in absolute effect sizes for
putamen and pallidum after removing individuals with a
neurodevelopmental diagnosis (Supplementary Table 5).
This is consistent with the enlargements of putamen and
pallidum associated with duration of illness in schizo-
phrenia [46], which may partly reflect the cumulative effect
of antipsychotic medication on basal ganglia volumes [47].
The observed dose response effect on ICV is in agreement
with previous findings on head circumference [17], as are
the dose response effect on BMI (Supplementary Figure 6,
Supplementary Table 10) [17, 31]. One of the strengths of
this study is the inclusion of non-clinical samples allowing
for estimates closer to the actual carrier population.
Unfortunately, the small number of CNV cases does not
provide enough power to investigate preferential alterations
in deletion or duplication carriers.
To conclude, the present findings of negative dose-
response effects of copy number on ICV and volumes of
caudate, pallidum and putamen, with no effect on cortical
measures, suggest a specific effect on basal ganglia structures
of the 16p11.2 distal CNV. These results provide novel
insight into genetic factors determining basal ganglia volumes
and suggest specific pathobiological mechanisms involved in
the development of neurodevelopmental disorders.
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